KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapy

Biomaterials

Volumn 97, Issue , 2016, Pages 22-33

  Chen, Guojun ^a,b   Jaskula Sztul, Renata ^c   Harrison, April ^d   Dammalapati, Ajitha ^d   Xu, Wenjin ^a,b   Cheng, Yiqiang ^e   Chen, Herbert ^c   Gong, Shaoqin ^a,b  

^a University of Wisconsin Madison   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

HDAC inhibitor; KE108 peptide; Neuroendocrine cancers; Somatostatin receptor; Targeted drug delivery; Unimolecular micelles

Indexed keywords

BLOCK COPOLYMERS; CELL CULTURE; CELLS; HYDROPHOBICITY; INFRARED DEVICES; JOINTS (ANATOMY); MICELLES; ONCOLOGY; PEPTIDES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; TUMORS;

HDAC INHIBITORS; NEUROENDOCRINE CANCERS; SOMATOSTATIN RECEPTORS; TARGETED DRUG DELIVERY; UNIMOLECULAR MICELLES;

DISEASES;

HISTONE DEACETYLASE INHIBITOR; KE 108; MACROGOL; POLYAMIDOAMINE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 5; THAILANDEPSIN A; UNCLASSIFIED DRUG; CYCLOPEPTIDE; DEPSIPEPTIDE; POLYMER; SOMATOSTATIN RECEPTOR; TYR(0)-(CYCLO-D-DAB-ARG-PHE-PHE-D-TRP-LYS-THR-PHE);

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG STABILITY; DRUG TARGETING; FLUORESCENCE IMAGING; GENE OVEREXPRESSION; HYDROPHOBICITY; IN VIVO STUDY; MALE; MICELLE; MOLECULARLY TARGETED THERAPY; MOUSE; NEUROENDOCRINE CANCER; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; HUMAN; HYDRODYNAMICS; INFRARED SPECTROSCOPY; METABOLISM; NUDE MOUSE; PARTICLE SIZE; PATHOLOGY; PROTON NUCLEAR MAGNETIC RESONANCE; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DEPSIPEPTIDES; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDRODYNAMICS; MALE; MICE, NUDE; MICELLES; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; PARTICLE SIZE; PEPTIDES, CYCLIC; POLYMERS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; RECEPTORS, SOMATOSTATIN; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TISSUE DISTRIBUTION;

EID: 84964907524     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.04.029     Document Type: Article

References (54)

1. Chen H. Therapeutic options for patients with metastatic gastrointestinal carcinoid. J. Surg. Oncol. 2008, 97:203-204.
2. Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008, 26:3063-3072.
3. Adler J.T., Meyer-Rochow G.Y., Chen H., Benn D.E., Robinson B.G., Sippel R.S., et al. Pheochromocytoma: current approaches and future directions. The Oncologist 2008, 13:779-793.
4. Frilling A., Akerstrom G., Falconi M., Pavel M., Ramos J., Kidd M., et al. Neuroendocrine tumor disease: an evolving landscape. Endocr. Relat. 2012, 19:R163-R185.
5. Pitt S.C., Moley J.F. Medullary, anaplastic, and metastatic cancers of the thyroid. Semin. Oncol. 2010, 37:567-579.
6. Sippel R.S., Kunnimalaiyaan M., Chen H. Current management of medullary thyroid cancer. The Oncologist 2008, 13:539-547.
7. Lal A., Chen H. Treatment of advanced carcinoid tumors. Curr. Opin. Oncol. 2006, 18:9-15.
8. Jaskula-Sztul R., Eide J., Tesfazghi S., Dammalapati A., Harrison A.D., Yu X.M., et al. Tumor-suppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction. Mol. Cancer Ther. 2015, 14:499-512.
9. Greenblatt D.Y., Vaccaro A.M., Jaskula-Sztul R., Ning L., Haymart M., Kunnimalaiyaan M., et al. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. The Oncologist 2007, 12:942-951.
10. Jaskula-Sztul R., Pisarnturakit P., Landowski M., Chen H., Kunnimalaiyaan M. Expression of the active Notch1 decreases MTC tumor growth in vivo. J. Surg. Res. 2011, 171:23-27.
11. Weinlander E., Somnay Y., Harrison A.D., Wang C., Cheng Y.Q., Jaskula-Sztul R., et al. The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth. J. Surg. Res. 2014, 190:191-197.
12. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39.
13. Lee H.Z., Kwitkowski V.E., Del Valle P.L., Ricci M.S., Saber H., Habtemariam B.A., et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2015, 21:2666-2670.
14. VanderMolen K.M., McCulloch W., Pearce C.J., Oberlies N.H. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J. Antibiot. 2011, 64:525-531.
15. Wang C., Henkes L.M., Doughty L.B., He M., Wang D., Meyer-Almes F.J., et al. Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities. J. Nat. Prod. 2011, 74:2031-2038.
16. Xiao K., Li Y.P., Wang C., Ahmad S., Vu M., Kuma K., et al. Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer. Biomaterials 2015, 67:183-193.
17. Jaskula-Sztul R., Dammalapati A., Korlesky C., Gong S., Cheng Y.Q., Chen H. Thailandepsin A, a new HDAC inhibitor, reduces cellular proliferation and activates the Notch pathway in human carcinoids cancer cells. Cancer Res. 2013, 73:1014.
18. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
19. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 2012, 63:185-198.
20. Pan L., He Q., Liu J., Chen Y., Ma M., Zhang L., et al. Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles. J. Am. Chem. Soc. 2012, 134:5722-5725.
21. Nicolas J., Mura S., Brambilla D., Mackiewicz N., Couvreur P. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem. Soc. Rev. 2013, 42:1147-1235.
22. Dhar S., Gu F.X., Langer R., Farokhzad O.C., Lippard S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17356-17361.
23. Liong M., Lu J., Kovochich M., Xia T., Ruehm S.G., Nel A.E., et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. Acs Nano 2008, 2:889-896.
24. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
25. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 2007, 24:1-16.
26. Kedar U., Phutane P., Shidhaye S., Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomed. Nanotechnol. Biol. Med. 2010, 6:714-729.
27. Adams M.L., Lavasanifar A., Kwon G.S. Amphiphilic block copolymers for drug delivery. J. Pharm. Sci. 2003, 92:1343-1355.
28. Lavasanifar A., Samuel J., Kwon G.S. Poly (ethylene oxide)-block-poly (L-amino acid) micelles for drug delivery. Adv. Drug Deliv. Rev. 2002, 54:169-190.
29. Heise A., Hedrick J.L., Frank C.W., Miller R.D. Starlike block copolymers with amphiphilic arms as models for unimolecular micelles. JACS 1999, 121:8647-8648.
30. Lawrence M.J. Surfactant systems: their use in drug delivery. Chem. Soc. Rev. 1994, 23:417-424.
31. Kim S., Shi Y., Kim J., Park K., Cheng J. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. Expert Opin. Drug Deliv. 2010, 7:49-62.
32. Prabaharan M., Grailer J.J., Pilla S., Steeber D.A., Gong S. Folate-conjugated amphiphilic hyperbranched block copolymers based on Boltorn H40, poly(L-lactide) and poly(ethylene glycol) for tumor-targeted drug delivery. Biomaterials 2009, 30:3009-3019.
33. Prabaharan M., Grailer J.J., Pilla S., Steeber D.A., Gong S.Q. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery. Biomaterials 2009, 30:5757-5766.
34. Guo J., Hong H., Chen G., Shi S., Zheng Q., Zhang Y., et al. Image-guided and tumor-targeted drug delivery with radiolabeled unimolecular micelles. Biomaterials 2013, 34:8323-8332.
35. Xiao Y., Hong H., Javadi A., Engle J.W., Xu W., Yang Y., et al. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 2012, 33:3071-3082.
36. Xu W., Siddiqui I.A., Nihal M., Pilla S., Rosenthal K., Mukhtar H., et al. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials 2013, 34:5244-5253.
37. Xu W., Burke J.F., Pilla S., Chen H., Jaskula-Sztul R., Gong S. Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapy. Nanoscale 2013, 5:9924-9933.
38. Yang X., Grailer J.J., Pilla S., Steeber D.A., Gong S. Tumor-targeting, pH-responsive, and stable unimolecular micelles as drug nanocarriers for targeted cancer therapy. Bioconjug. Chem. 2010, 21:496-504.
39. Guo J., Hong H., Chen G., Shi S., Nayak T.R., Theuer C.P., et al. Theranostic unimolecular micelles based on brush-shaped amphiphilic block copolymers for tumor-targeted drug delivery and positron emission tomography imaging. ACS Appl. Mater. Interfaces 2014, 6:21769-21779.
40. Chen G., Wang L., Cordie T., Vokoun C., Eliceiri K.W., Gong S. Multi-functional self-fluorescent unimolecular micelles for tumor-targeted drug delivery and bioimaging. Biomaterials 2015, 47:41-50.
41. Xiao Y., Jaskula-Sztul R., Javadi A., Xu W., Eide J., Dammalapati A., et al. Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. Nanoscale 2012, 4:7185-7193.
42. Sun L.-C., Coy D.H. Somatostatin receptor-targeted anti-cancer therapy. Curr. Drug Deliv. 2011, 8:2-10.
43. Pinchot S.N., Holen K., Sippel R.S., Chen H. Carcinoid tumors. The Oncologist 2008, 13:1255-1269.
44. Shimon L., Taylor J.E., Dong J.Z., Bitonte R.A., Kim S., Morgan B., et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. J. Clin. Investig. 1997, 99:789-798.
45. Zhou Y., Xiao X., Li Y., Zhou T. Somatostatin analogues inhibit cancer cell proliferation in an SSTR2-dependent manner via both cytostatic and cytotoxic pathways. Oncol. Rep. 1994, 21:379-386.
46. Jiang H., Deng X.F., Duan C.M., Chen C., Xiang J.L., Lu Y., et al. Somatostatin receptors SSTR2 and SSTR5 are expressed in the human thoracic duct. Lymphology 2011, 44:21-28.
47. Reubi J.C., Eisenwiener K.-P., Rink H., Waser B., Macke H.R. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur. J. Pharmacol. 2002, 456:45-49.
48. Jaskula-Sztul R., Xu W., Chen G., Harrison A., Dammalapati A., Nair R., et al. Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapy. Biomaterials 2016, 91:1-10.
49. Huo M., Zou A., Yao C., Zhang Y., Zhou J., Wang J., et al. Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles. Biomaterials 2012, 33:6393-6407.
50. Martinez-Alonso M., Llecha N., Mayorga M., Sorolla A., Dolcet X., Sanmartin V., et al. Expression of somatostatin receptors in human melanoma cell lines effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation. J. Int. Med. Res. 2009, 37:1813-1822.
51. Liang P., Zhao D., Wang C.Q., Zong J.Y., Zhuo R.X., Cheng S.X. Facile preparation of heparin/CaCO3/CaP hybrid nano-carriers with controllable size for anticancer drug delivery. Colloids Surf. B Biointerfaces 2013, 102:783-788.
52. Miller D.W., Batrakova E.V., Waltner T.O., Alakhov V.Y., Kabanov A.V. Interactions of pluronic block copolymers with brain microvessel enothelial cells: evidence of two potential pathways for drug absorption. Bioconjug. Chem. 1997, 8:649-657.
53. Oberg K., Janson E.T., Eriksson B. Tumour markers in neuroendocrine tumours. Ital. J. Gastroenterol. Hepatol. 1999, 31:S160-S162.
54. Chen H., Udelsman R., Zeiger M.A., Ball D.W. Human achaete-scute homolog-1 is highly expressed in a subset of neuroendocrine tumors. Oncol. Rep. 1997, 4:775-778.